Replies to post #171448 on Biotech Values

[ronpopeil]

I'm holding ENTA. I am hoping ENTA/ABBV will still be very competitive.

[ciotera]

Clear indication of longer dosing advantage

Would you personally care to stay on the regimen twice as long (and incur the additional costs) to get from 94% to 97% SVR? Is this even a statistically significant difference? Not to mention clinically meaningful?

[DewDiligence]

GILD—Clear indication of longer dosing advantage in both naive and treatment-experienced patients.

Agree for the 12w-vs-8w comparison, but not for the 24w-vs-12w comparison.